HC Wainwright Cuts Y-mAbs Therapeutics (NASDAQ:YMAB) Price Target to $12.00

Y-mAbs Therapeutics (NASDAQ:YMAB - Free Report) had its price objective decreased by HC Wainwright from $22.00 to $12.00 in a research report released on Friday,Benzinga reports. HC Wainwright currently has a buy rating on the stock.

YMAB has been the subject of several other reports. Truist Financial dropped their target price on shares of Y-mAbs Therapeutics from $21.00 to $18.00 and set a "buy" rating for the company in a research report on Wednesday, March 5th. Bank of America dropped their price objective on shares of Y-mAbs Therapeutics from $14.00 to $12.00 and set a "neutral" rating for the company in a report on Wednesday, March 5th. Brookline Capital Management began coverage on Y-mAbs Therapeutics in a research note on Thursday, December 5th. They issued a "buy" rating and a $17.00 target price on the stock. Morgan Stanley dropped their price target on Y-mAbs Therapeutics from $11.00 to $7.00 and set an "underweight" rating for the company in a research note on Wednesday, March 5th. Finally, Wedbush reiterated an "outperform" rating and issued a $23.00 price objective on shares of Y-mAbs Therapeutics in a report on Monday, March 3rd. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, seven have assigned a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $18.30.

Remove Ads

Y-mAbs Therapeutics Price Performance

Shares of NASDAQ YMAB traded up $0.03 during trading on Friday, reaching $5.03. 97,950 shares of the stock traded hands, compared to its average volume of 328,789. The company has a 50-day moving average of $5.71 and a 200-day moving average of $9.77. Y-mAbs Therapeutics has a 52-week low of $4.25 and a 52-week high of $17.78. The stock has a market capitalization of $227.45 million, a P/E ratio of -9.31 and a beta of 0.65.

Y-mAbs Therapeutics (NASDAQ:YMAB - Get Free Report) last posted its quarterly earnings results on Tuesday, March 4th. The company reported ($0.15) EPS for the quarter, missing analysts' consensus estimates of ($0.13) by ($0.02). The company had revenue of $26.50 million during the quarter, compared to the consensus estimate of $26.70 million. Y-mAbs Therapeutics had a negative return on equity of 24.61% and a negative net margin of 28.22%. During the same period in the previous year, the business earned ($0.02) earnings per share. Analysts expect that Y-mAbs Therapeutics will post -0.65 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Y-mAbs Therapeutics news, insider Thomas Gad sold 10,810 shares of the company's stock in a transaction that occurred on Friday, March 7th. The stock was sold at an average price of $5.23, for a total transaction of $56,536.30. Following the sale, the insider now directly owns 202,721 shares in the company, valued at $1,060,230.83. This represents a 5.06 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this link. 22.50% of the stock is owned by company insiders.

Institutional Investors Weigh In On Y-mAbs Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the business. Paradigm Biocapital Advisors LP grew its stake in Y-mAbs Therapeutics by 3.7% in the 4th quarter. Paradigm Biocapital Advisors LP now owns 4,236,346 shares of the company's stock worth $33,171,000 after acquiring an additional 150,000 shares in the last quarter. Acorn Capital Advisors LLC bought a new position in Y-mAbs Therapeutics in the fourth quarter worth approximately $22,408,000. Caligan Partners LP increased its holdings in Y-mAbs Therapeutics by 47.9% during the 4th quarter. Caligan Partners LP now owns 1,767,982 shares of the company's stock worth $13,843,000 after purchasing an additional 572,729 shares during the period. State Street Corp raised its position in Y-mAbs Therapeutics by 50.4% during the 3rd quarter. State Street Corp now owns 1,209,781 shares of the company's stock valued at $15,909,000 after purchasing an additional 405,169 shares in the last quarter. Finally, Geode Capital Management LLC lifted its holdings in shares of Y-mAbs Therapeutics by 1.1% in the 4th quarter. Geode Capital Management LLC now owns 822,309 shares of the company's stock worth $6,440,000 after buying an additional 8,820 shares during the period. 70.85% of the stock is currently owned by hedge funds and other institutional investors.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.